Last reviewed 2026-06-10 · How we verify

Routine vaccination of adolescents 11 through 12 years of age — Treatment Landscape & Competitive Intelligence

Routine vaccination of adolescents 11 through 12 years of age (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Routine vaccination of adolescents 11 through 12 years of age, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer · 1 drug in Routine vaccination of adolescents 11 through 12 years of age

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Routine vaccination of adolescents 11 through 12 years of age:

• Routine vaccination of adolescents 11 through 12 years of age treatment updates — RSS
• Routine vaccination of adolescents 11 through 12 years of age treatment updates — Atom
• Routine vaccination of adolescents 11 through 12 years of age treatment updates — JSON

Cite this brief

Drug Landscape (2026). Routine vaccination of adolescents 11 through 12 years of age — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/routine-vaccination-of-adolescents-11-through-12-years-of-age. Accessed 2026-06-10.

Related

• Routine vaccination of adolescents 11 through 12 years of age full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing